Article Details

Dicerna Pharmaceuticals (NASDAQ:DRNA) Earns "Buy" Rating from HC Wainwright

Retrieved on: 2021-06-23 11:48:45

Tags for this article:

Click the tags to see associated articles and topics

Dicerna Pharmaceuticals (NASDAQ:DRNA) Earns "Buy" Rating from HC Wainwright. View article details on hiswai:

Excerpt

Truist Securities boosted their target price on shares of Dicerna Pharmaceuticals from $35.00 to $45.00 in a research note on Monday, April 19th.

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up